Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
NEW YORK (TheStreet) -- Did you miss last night's "Mad Money" on CNBC? If so, here are Jim Cramer's top takeaways for today's trading.
Lilly's problem has been the fact that two of its biggest drugs, Cymbalta and Evista, lost patent protection last year, taking almost 30% of Lilly's profits along with it. Investors feared that Lilly had nothing in the pipeline to replace these blockbusters drugs, and up until recently they've been right.
But last Thursday, Lilly released more positive data for its diabetes drug Jardiance, news that sent shares up 6.5% on the day and a full 23% for 2015. While Jardiance is already on the market, analysts now predict the drug could hit peak sales of $6 billion a year, thanks to its new cardiovascular benefits. Impressive, Cramer noted.
Then there's Lilly's Alzheimer's drug, which is also showing positive results in at least slowing the progress of a disease with very few options.
Caterpillar (CAT) - Get Report : It doesn't matter how good your products are if your clients don't need it, Cramer told viewers. That certainly looks to be the case with Caterpillar, which today announced a huge revenue shortfall and the laying off of over 10,000 workers as the company struggles with three years of falling sales.
Caterpillar is a victim of the decline in mining and manufacturing, Cramer explained. The coal industry continues to shrink faster than anyone thought and the need fro heavy oil just isn't economical at lower oil prices.
In fact, Caterpillar's only bright spot was construction, but even there the strength appears to be a domestic-only phenomenon.
So what should investors do with this stock that's now down 28% for the year with a 4% yield? Cramer said normally, he'd be telling you to buy, buy, buy, but in this case, the revenue forecasts may still be too optimistic, which means there's likely a lot more pain ahead for Caterpillar as it right-sizes its operations for the new global realities.
Opko Health (OPK) - Get Report : For his "Executive Decision" segment, Cramer spoke with Dr. Phillip Frost, chairman and CEO of Opko Health, a stock that's been more than cut in half after the company announced the acquisition of Bioreference Labs earlier this year.
Frost said that Bioreference has been the "most interesting" acquisition he's ever made. For a 14% dilution of its stock, Opko receives $1 billion in revenue and $100 million in operating income, as well as 400 dedicated salespeople to help spread the work about the company's products.
Frost reiterated that Opko's prostate tests have the potential to eliminate up to 50% of all prostate biopsies performed every year, a great savings to both patients and the health care system.
Cramer said the synergies between the companies make a lot of sense and he remains a believer in both Frost and Opko.
To read a full recap of "Mad Money" on CNBC, click here.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.
At the time of publication, Cramer's Action Alerts PLUS had no position in stocks mentioned.